Table 2.

Second-line treatment patterns in patients who received at least second-line therapy of adv/met ESCC

	All ≥ 2L patients (n = 86)	2L taxane therapy (n = 37)	2L non-taxane therapy (n = 49)
Taxanes	37 (43.0)	37 (100.0)	0
Fluoropyrimidine–platinum	25 (29.1)	0	25 (51.0)
Fluoropyrimidine	14 (16.3)	0	14 (28.6)
ECF/DCF	2 (2.3)	0	2 (4.1)
Other	8 (9.3)	0	8 (16.3)

Adv/met unresectable locally advanced, recurrent or metastatic, DCF docetaxel, cisplatin and fluorouracil, ECF epirubicin, cisplatin and fluorouracil